UroGen Pharma (FRA:UR8) FCF Margin %: -89.03% (As of Mar. 2026)

What is UroGen Pharma FCF Margin %?

UroGen Pharma FRA:UR8 -3.22% 67 FCF Margin % is -89.03% as of Mar. 2026. GuruFocus rates FRA:UR8 with a GF Score™ of 67/100 and a GF Value™ of €17.05 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 958 Biotechnology companies, UroGen Pharma ranks worse than 54.7% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. UroGen Pharma's Free Cash Flow for the three months ended in Mar. 2026 was €-39.2 Mil. UroGen Pharma's Revenue for the three months ended in Mar. 2026 was €44.1 Mil. Therefore, UroGen Pharma's FCF Margin % for the quarter that ended in Mar. 2026 was -89.03%.

As of today, UroGen Pharma's current FCF Yield % is -9.89%.

The historical rank and industry rank for UroGen Pharma's FCF Margin % or its related term are showing as below:

FRA:UR8' s FCF Margin % Range Over the Past 10 Years
Min: -396344.44 Med: -142.34 Max: 19.93
Current: -118.15

During the past 11 years, the highest FCF Margin % of UroGen Pharma was 19.93%. The lowest was -396344.44%. And the median was -142.34%.

FRA:UR8's FCF Margin % is ranked worse than
54.7% of 958 companies
in the Biotechnology industry
Industry Median: -85.21 vs FRA:UR8: -118.15

UroGen Pharma FCF Margin % Related Terms

UroGen Pharma FCF Margin % Historical Data

* Premium members only.

The historical data trend for UroGen Pharma's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

UroGen Pharma FCF Margin % Chart

UroGen Pharma Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

FCF Margin %

Get a 7-Day Free Trial

-178.27

-136.45

-92.57

-107.37

-148.22

UroGen Pharma Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
FCF Margin %	Get a 7-Day Free Trial															-207.70	-165.05	-154.12	-101.34	-89.03

FRA:UR8 vs OCS, SEPN, AVBP: FCF Margin % Comparison

For the Biotechnology subindustry, UroGen Pharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

UroGen Pharma FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, UroGen Pharma's FCF Margin % distribution charts can be found below:

* The bar in red indicates where UroGen Pharma's FCF Margin % falls into.

Save Embed

67GF Score

UroGen Pharma Ltd FRA:UR8

FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

UroGen Pharma FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

UroGen Pharma's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-138.974	/	93.759
	=	-148.22 %

UroGen Pharma's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-39.245	/	44.08
	=	-89.03 %

Frequently Asked Questions Learn more about FCF Margin % →

What does a FCF Margin % of -89.03% mean?

UroGen Pharma (FRA:UR8) has a FCF Margin % of -89.03% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on UroGen Pharma and its competitors. According to the industry distribution chart, UroGen Pharma ranks #524 out of 958 companies in the Biotechnology industry, placing it in the top 54.7%.

Is UroGen Pharma's FCF Margin % too high?

UroGen Pharma's current FCF Margin % is -89.03%. Based on the distribution chart, UroGen Pharma ranks #524 out of 958 companies in the Biotechnology industry, which is below the industry midpoint. Overall, UroGen Pharma has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does UroGen Pharma's FCF Margin % compare to OCS and SEPN?

According to the Biotechnology industry distribution chart, UroGen Pharma ranks #524 out of 958 companies for FCF Margin %. This places UroGen Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good FCF Margin % for a Biotechnology company?

A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high FCF Margin % mean?

A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on UroGen Pharma and its competitors. UroGen Pharma's current FCF Margin % is -89.03%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is UroGen Pharma stock overvalued right now?

Based on GuruFocus' analysis, UroGen Pharma (FRA:UR8) is currently considered Significantly Overvalued. The stock's GF Value™ is €17.05, compared to a current price of €29.44 — trading 72.7% above its estimated fair value. The current FCF Margin % is -89.03%. UroGen Pharma's overall GF Score™ is 67/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is FCF Margin % calculated?

FCF Margin % is calculated from a company's financial statements. For UroGen Pharma (FRA:UR8), the current FCF Margin % is -89.03% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is UroGen Pharma (FRA:UR8) Overvalued in 2026?

Based on GuruFocus' analysis, UroGen Pharma stock appears to be overvalued. The current stock price of €29.44 is trading 72.7% above its estimated GF Value™ of €17.05. GuruFocus considers UroGen Pharma to be Significantly Overvalued.

Key valuation signals for FRA:UR8:

FCF Margin %: -89.03%
GF Value™: €17.05 vs. price of €29.44 (72.7% above fair value)
GF Score™: 67/100 with 9 warning signs

No single metric tells the full story. See the FRA:UR8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

UroGen Pharma Business Description

Industry Healthcare Biotechnology

Comparable Companies OCS SEPN AVBP MLTX MPLT COAG BCAX KALV FTRE MAZE VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges URGN:USA 0XOD:UK

Address 400 Alexander Park Drive, 4th Floor, Princeton, NJ, USA, 08540

Website https://www.urogen.com

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

67GF Score

Get the complete analysis for FRA:UR8

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€29.44

Price

€17.05

GF Value

View FRA:UR8 Analysis

See FCF Margin % data for all stocks →